About us
Services & Solutions
Chemistry Drug Metabolism and Pharmacokinetics (DMPK) Discovery Biology Oncology Pharmacology Biologics
Medicinal Chemistry Parallel Synthesis Peptide Chemistry Computational Chemistry Synthetic Chemistry Analytical Chemistry Scale Up Chemistry
In Vivo PK and TK In Vitro ADME Bioanalytical Service Exploratory Toxicity In Rodents, Dogs and Monkeys Large Molecules Capabilities Bioanalytical Instruments
Fragment Based Drug Discovery (FBDD) Biochemical Assays Cellular Assays Protein Science Assay Technologies Biophysics SPR Safety Pharmacology Screening Services Key Instruments
PDX CDX Orthotopic Models Syngeneic Models Humanized Mouse Models CAR-T and CAR-NK Mouse Models In Vitro Assays
Immunology Inflammation Metabolic NASH/MASH Respiratory Neuroscience
Systematic Antibody Discovery Service
Process R&D Scale Up Synthesis DS Manufacturing
Flow Chemistry Sugar Chemistry Peptide Chemistry Preparative Purification Capacity Process Safety Assessment
Synthetic and Scale Up Chemistry
Kilo and Pilot Scale Production RSM and Intermediates Manufacturing QA EHS
Preformulation Formulation, Analytical, and Process Development Drug Product Manufacturing
Bioavailability Enhancement Modified Release
Commercial Manufacturing
Platforms
News & Resources
Careers
Contact us
×

news

Company News Events Insights Webinars Virtual Tours

Lynk Pharmaceuticals Presents Long-Term Outstanding Service Award to BioDuro-Sundia Chemistry Team

Lynk Pharmaceuticals awarded BioDuro-Sundia's chemistry team the Long-Term Outstanding Service Award in Shanghai recognizing their exceptional contributions.
September 25, 2023

Congratulate Zhiben Pharma for Receiving China CDE Implied License to Initiate Clinical Trials for Antimicrobial Drug ZB-001

Congratulate Zhiben Pharma for Receiving China CDE Implied License to Initiate Clinical Trials for Antimicrobial Drug ZB-001 | BioDuro-Sundia | Moving You Forward
August 01, 2023

BioDuro-Sundia Jiangsu Site Re-establishes Legacy Operations in Radiometric Assays

BioDuro-Sundia's Jiangsu site re-established legacy radiometric assay operations in July 2023, enhancing their assay technologies to support in vitro drug ...
July 06, 2023

Salubris Pharmaceuticals SAL0119 IND Application for Treatment of Ankylosing Spondylitis and Rheumatoid Arthritis Accepted by FDA

Salubris Pharmaceuticals SAL0119 IND Application for Treatment of Ankylosing Spondylitis and Rheumatoid Arthritis Accepted by FDA | BioDuro-Sundia
June 30, 2023

BioDuro-Sundia Forms Strategic Partnership with GS Capsule

BioDuro-Sundia and GS Capsule forge a strategic partnership at CPHI China, enhancing drug formulation and packaging innovations for global healthcare solutions.
June 19, 2023
Total 88 12345678...1718
Subscribe to BioDuro-Sundia
Receive our newsletter and information on upcoming events
Your trusted partner from drug discovery and
development to commercialization

Home

About us

Services & Solutions

Platforms

News & Resources

Careers

Contact us

Explore

Discovery

Drug Substance

Drug Product

© 2023 BioDuro-Sundia. All rights reserved
Terms of Use Privacy Policy
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all